

Breast Cancer Medications

*generic version available

E experimental

Chemotherapy Medications [Learn more >>](#) [More >>](#)

DRUG	GENERIC NAME	DRUG INDICATION
Chemotherapy	Multiple	Cytotoxic chemotherapy, the oldest and most commonly used type of cancer treatment, halts cell division and kills rapidly growing cells. For a full list of chemotherapy drugs, click here .

Hormone Therapy Medications [Learn more >>](#) [More >>](#)

DRUG	GENERIC NAME	DRUG INDICATION
Arimidex	anastrozole	Arimidex is an aromatase inhibitor approved for adjuvant (post-surgery) treatment of hormone receptor-positive (HR+) early breast cancer and first-line or subsequent treatment of HR+ advanced or metastatic breast cancer in postmenopausal women.
Aromasin	exemestane	Aromasin is an aromatase inhibitor approved for adjuvant (post-surgery) treatment of estrogen receptor-positive (ER+) early breast cancer and treatment of ER+ advanced breast cancer in postmenopausal women who previously used tamoxifen.
Evista	raloxifene	Evista is a selective estrogen receptor modulator approved for the prevention of breast cancer in high-risk postmenopausal women and women with osteoporosis (bone loss). It is not approved for the treatment of invasive breast cancer or to reduce the risk of cancer recurrence.

DRUG	GENERIC NAME	DRUG INDICATION
Fareston	toremifene	Fareston is a selective estrogen receptor modulator approved for the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive tumors or those with unknown receptor status.
Faslodex	fulvestrant	Faslodex is an estrogen receptor downregulator approved for the treatment of hormone receptor-positive advanced or metastatic breast cancer in postmenopausal women.
Femara	letrozole	Femara is an aromatase inhibitor approved for adjuvant (post-surgery) treatment of hormone receptor-positive (HR+) early breast cancer and treatment of HR+ advanced breast cancer in postmenopausal women.
Lupron	leuprolide	Lupron is a GnRH agonist approved for palliative treatment of advanced prostate cancer. It is also used to treat breast and ovarian cancer, though it is not FDA-approved for these indications.
Tamoxifen	tamoxifen	Tamoxifen is a selective estrogen receptor modulator approved for adjuvant (post-surgery) treatment to prevent recurrence or spread of early breast cancer and for treatment of women and men with advanced or metastatic breast cancer. It is also used to prevent breast cancer in high-risk women. It is sometimes used to treat ovarian cancer, though it is not FDA-approved for this indication.
Zoladex	goserelin	Zoladex is a GnRH agonist approved for palliative treatment of advanced prostate cancer and, treatment of localized prostate cancer in combination with Eulexin (flutamide) and palliative treatment of breast cancer in premenopausal women. It is also used to treat ovarian cancer, though it is not FDA-approved for this indication.

Immunotherapy Medications [Learn more >>](#) [More >>](#)

DRUG	GENERIC NAME	DRUG INDICATION
Keytruda	pembrolizumab	Keytruda is a PD-1 checkpoint inhibitor approved for inoperable or metastatic melanoma, adjuvant treatment of melanoma after surgery, non-small-cell lung cancer, bladder (urothelial) cancer, head and neck cancer, esophageal cancer, liver cancer, kidney cancer, stomach cancer, classic Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, Merkel cell carcinoma, cutaneous squamous cell carcinoma and pre- and post-surgery treatment of triple-negative breast cancer. It is also approved for all metastatic solid tumors with high microsatellite instability or mismatch repair deficiency mutations (MSI-H/dMMR) or high tumor mutation burden.

Targeted Therapy Medications [Learn more >>](#) [More >>](#)

DRUG	GENERIC NAME	DRUG INDICATION
Afinitor	everolimus	Afinitor is a kinase inhibitor approved for the treatment of hormone receptor-positive, HER2-negative advanced breast cancer in previously treated postmenopausal women, as well as for advanced kidney cancer and advanced or metastatic neuroendocrine tumors of the lung, pancreas, and gastrointestinal tract.
Enhertu	fam-trastuzumab deruxtecan-nxki	Enhertu is a HER2 antibody combined with a chemotherapy drug. It is approved for previously treated people with inoperable or metastatic HER2-positive breast cancer and for people with locally advanced or metastatic HER2-positive stomach or gastroesophageal junction cancer.
Herceptin	trastuzumab	Herceptin is a HER2 inhibitor approved for adjuvant (post-surgery) therapy of early breast cancer and treatment of metastatic breast cancer, stomach cancer and esophageal cancer that overexpresses human epidermal growth factor receptor 2.
Ibrance	palbociclib	Ibrance is a CDK4/6 kinase inhibitor approved for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in combination with hormone therapy.

DRUG	GENERIC NAME	DRUG INDICATION
Kadcyla	ado-trastuzumab emtansine	Kadcyla is a HER2 inhibitor combined with a chemotherapy drug. It is approved for people with HER2-positive metastatic breast cancer who were previously treated with Herceptin and chemotherapy and for adjuvant (post-surgery) therapy for early breast cancer.
Kisqali	ribociclib	Kisqali is a CDK4/6 kinase inhibitor approved for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in combination with hormone therapy.
Lynparza	olaparib	Lynparza is a PARP inhibitor approved for the treatment of advanced ovarian cancer in previously treated people with harmful BRCA mutations, maintenance treatment of ovarian cancer in people responding to chemotherapy, previously treated HER2-negative metastatic breast cancer in people with BRCA mutations, maintenance treatment of pancreatic cancer in people with BRCA mutations and previously treated metastatic castration-resistant prostate cancer in people with BRCA or other faulty DNA repair mutations.
Margenza	margetuximab	Margenza is a HER2 antibody approved for people with metastatic HER2-positive breast cancer who were previously treated with at least two other anti-HER2 inhibitors.
Nerlynx	neratinib	Nerlynx is a kinase inhibitor approved for extended adjuvant (post-surgery) treatment of early breast cancer that overexpresses human epidermal growth factor receptor 2 in people who previously used Herceptin.
Perjeta	pertuzumab	Perjeta is a HER2 inhibitor approved for neoadjuvant (pre-surgery) or adjuvant (post-surgery) treatment of early breast cancer, in combination with Herceptin (trastuzumab) and chemotherapy. This combination is also approved for previously untreated metastatic breast cancer.
Phesgo	Pertuzumab/trastuzumab/ hyaluronidase	Phesgo is an injectable fixed-dose combination regimen containing pertuzumab, trastuzumab and hyaluronidase that can be administered by a health care provider at home. It is approved for people with early or metastatic HER2-positive breast cancer.

DRUG	GENERIC NAME	DRUG INDICATION
Piqray	alpelisib	Piqray is a PI3K kinase inhibitor approved for the treatment of postmenopausal women, and men, with HER2-negative advanced or metastatic breast cancer with PIK3CA mutations.
Rozlytrek	entrectinib	Rozlytrek is approved for the treatment of solid tumors anywhere in the body that have NTRK gene fusions and for ROS1-positive non-small-cell lung cancer.
Talzenna	talazoparib	Talzenna is a PARP inhibitor approved for HER2 negative locally advanced or metastatic breast cancer in people with harmful BRCA mutations.
Trodelvy	sacituzumab govitecan	Trodelvy is an antibody-drug conjugate approved for the treatment of metastatic triple-negative breast cancer and advanced bladder (urothelial) cancer.
Tukysa	tucatinib	Tukysa is a kinase inhibitor approved for use in combination therapy for people with previously treated inoperable or metastatic HER2-positive breast cancer, including cancer that has spread to the brain.
Tykerb	lapatanib	Tykerb is a kinase inhibitor approved in combination with chemotherapy for previously treated patients with HER2-positive metastatic breast cancer. It is also approved in combination with hormone therapy for postmenopausal women with both HER2-positive and hormone receptor-positive metastatic cancer.
Verzenio	abemaciclib	Verzenio is a CDK4/6 kinase inhibitor approved for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, alone or in combination with hormone therapy.
Vitrakvi	larotrectinib	Vitrakvi is a TRK inhibitor that works against cancers anywhere in the body with NTRK gene fusions.

DRUG [Chemotherapy](#)

GENERIC NAME Multiple

DRUG INDICATION

Cytotoxic chemotherapy, the oldest and most commonly used type of cancer treatment, halts cell division and kills rapidly growing cells. For a full list of chemotherapy drugs, [click here](#).

DRUG [Arimidex](#)

GENERIC NAME anastrozole

DRUG Arimidex**DRUG INDICATION**

Arimidex is an aromatase inhibitor approved for adjuvant (post-surgery) treatment of hormone receptor-positive (HR+) early breast cancer and first-line or subsequent treatment of HR+ advanced or metastatic breast cancer in postmenopausal women.

DRUG Aromasin

GENERIC NAME exemestane

DRUG INDICATION

Aromasin is an aromatase inhibitor approved for adjuvant (post-surgery) treatment of estrogen receptor-positive (ER+) early breast cancer and treatment of ER+ advanced breast cancer in postmenopausal women who previously used tamoxifen.

DRUG Evista

GENERIC NAME raloxifene

DRUG INDICATION

Evista is a selective estrogen receptor modulator approved for the prevention of breast cancer in high-risk postmenopausal women and women with osteoporosis (bone loss). It is not approved for the treatment of invasive breast cancer or to reduce the risk of cancer recurrence.

DRUG Fareston

GENERIC NAME toremifene

DRUG INDICATION

Fareston is a selective estrogen receptor modulator approved for the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive tumors or those with unknown receptor status.

DRUG Faslodex

GENERIC NAME fulvestrant

DRUG INDICATION

Faslodex is an estrogen receptor downregulator approved for the treatment of hormone receptor-positive advanced or metastatic breast cancer in postmenopausal women.

DRUG Femara

GENERIC NAME letrozole

DRUG INDICATION

Femara is an aromatase inhibitor approved for adjuvant (post-surgery) treatment of hormone receptor-positive (HR+) early breast cancer and treatment of HR+ advanced breast cancer in postmenopausal women.

DRUG Lupron

GENERIC NAME leuprolide

DRUG INDICATION

Lupron is a GnRH agonist approved for palliative treatment of advanced prostate cancer. It is also used to treat breast and ovarian cancer, though it is not FDA-approved for these indications.

DRUG Tamoxifen**GENERIC NAME** tamoxifen**DRUG INDICATION**

Tamoxifen is a selective estrogen receptor modulator approved for adjuvant (post-surgery) treatment to prevent recurrence or spread of early breast cancer and for treatment of women and men with advanced or metastatic breast cancer. It is also used to prevent breast cancer in high-risk women. It is sometimes used to treat ovarian cancer, though it is not FDA-approved for this indication.

DRUG Zoladex**GENERIC NAME** goserelin**DRUG INDICATION**

Zoladex is a GnRH agonist approved for palliative treatment of advanced prostate cancer and, treatment of localized prostate cancer in combination with Eulexin (flutamide) and palliative treatment of breast cancer in premenopausal women. It is also used to treat ovarian cancer, though it is not FDA-approved for this indication.

DRUG Keytruda**GENERIC NAME** pembrolizumab**DRUG INDICATION**

Keytruda is a PD-1 checkpoint inhibitor approved for inoperable or metastatic melanoma, adjuvant treatment of melanoma after surgery, non-small-cell lung cancer, bladder (urothelial) cancer, head and neck cancer, esophageal cancer, liver cancer, kidney cancer, stomach cancer, classic Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, Merkel cell carcinoma, cutaneous squamous cell carcinoma and pre- and post-surgery treatment of triple-negative breast cancer. It is also approved for all metastatic solid tumors with high microsatellite instability or mismatch repair deficiency mutations (MSI-H/dMMR) or high tumor mutation burden.

DRUG Afinitor**GENERIC NAME** everolimus**DRUG INDICATION**

Afinitor is a kinase inhibitor approved for the treatment of hormone receptor-positive, HER2-negative advanced breast cancer in previously treated postmenopausal women, as well as for advanced kidney cancer and advanced or metastatic neuroendocrine tumors of the lung, pancreas, and gastrointestinal tract.

DRUG Enhertu**GENERIC NAME** fam-trastuzumab deruxtecan-nxki**DRUG INDICATION**

Enhertu is a HER2 antibody combined with a chemotherapy drug. It is approved for previously treated people with inoperable or metastatic HER2-positive breast cancer and for people with locally advanced or metastatic HER2-positive stomach or gastroesophageal junction cancer.

DRUG Herceptin**GENERIC NAME** trastuzumab

DRUG Herceptin**DRUG INDICATION**

Herceptin is a HER2 inhibitor approved for adjuvant (post-surgery) therapy of early breast cancer and treatment of metastatic breast cancer, stomach cancer and esophageal cancer that overexpresses human epidermal growth factor receptor 2.

DRUG Ibrance

GENERIC NAME palbociclib

DRUG INDICATION

Ibrance is a CDK4/6 kinase inhibitor approved for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in combination with hormone therapy.

DRUG Kadcyla

GENERIC NAME ado-trastuzumab emtansine

DRUG INDICATION

Kadcyla is a HER2 inhibitor combined with a chemotherapy drug. It is approved for people with HER2-positive metastatic breast cancer who were previously treated with Herceptin and chemotherapy and for adjuvant (post-surgery) therapy for early breast cancer.

DRUG Kisqali

GENERIC NAME ribociclib

DRUG INDICATION

Kisqali is a CDK4/6 kinase inhibitor approved for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in combination with hormone therapy.

DRUG Lynparza

GENERIC NAME olaparib

DRUG INDICATION

Lynparza is a PARP inhibitor approved for the treatment of advanced ovarian cancer in previously treated people with harmful BRCA mutations, maintenance treatment of ovarian cancer in people responding to chemotherapy, previously treated HER2-negative metastatic breast cancer in people with BRCA mutations, maintenance treatment of pancreatic cancer in people with BRCA mutations and previously treated metastatic castration-resistant prostate cancer in people with BRCA or other faulty DNA repair mutations.

DRUG Margenza

GENERIC NAME margetuximab

DRUG INDICATION

Margenza is a HER2 antibody approved for people with metastatic HER2-positive breast cancer who were previously treated with at least two other anti-HER2 inhibitors.

DRUG Nerlynx

GENERIC NAME neratinib

DRUG INDICATION

Nerlynx is a kinase inhibitor approved for extended adjuvant (post-surgery) treatment of early breast cancer that overexpresses human epidermal growth factor receptor 2 in people who previously used Herceptin.

DRUG Perjeta**GENERIC NAME** pertuzumab**DRUG INDICATION**

Perjeta is a HER2 inhibitor approved for neoadjuvant (pre-surgery) or adjuvant (post-surgery) treatment of early breast cancer, in combination with Herceptin (trastuzumab) and chemotherapy. This combination is also approved for previously untreated metastatic breast cancer.

DRUG Phesgo**GENERIC NAME** Pertuzumab/trastuzumab/hyaluronidase**DRUG INDICATION**

Phesgo is an injectable fixed-dose combination regimen containing pertuzumab, trastuzumab and hyaluronidase that can be administered by a health care provider at home. It is approved for people with early or metastatic HER2-positive breast cancer.

DRUG Piqray**GENERIC NAME** alpelisib**DRUG INDICATION**

Piqray is a PI3K kinase inhibitor approved for the treatment of postmenopausal women, and men, with HER2-negative advanced or metastatic breast cancer with PIK3CA mutations.

DRUG Rozlytrek**GENERIC NAME** entrectinib**DRUG INDICATION**

Rozlytrek is approved for the treatment of solid tumors anywhere in the body that have NTRK gene fusions and for ROS1-positive non-small-cell lung cancer.

DRUG Talzenna**GENERIC NAME** talazoparib**DRUG INDICATION**

Talzenna is a PARP inhibitor approved for HER2 negative locally advanced or metastatic breast cancer in people with harmful BRCA mutations.

DRUG Trodely**GENERIC NAME** sacituzumab govitecan**DRUG INDICATION**

Trodely is an antibody-drug conjugate approved for the treatment of metastatic triple-negative breast cancer and advanced bladder (urothelial) cancer.

DRUG Tukysa**GENERIC NAME** tucatinib**DRUG INDICATION**

Tukysa is a kinase inhibitor approved for use in combination therapy for people with previously treated inoperable or metastatic HER2-positive breast cancer, including cancer that has spread to the brain.

DRUG Tykerb**GENERIC NAME** lapatanib**DRUG INDICATION**

Tykerb is a kinase inhibitor approved in combination with chemotherapy for previously treated patients with HER2-positive metastatic breast cancer. It is also approved in combination with hormone therapy for postmenopausal women with both HER2-positive and hormone receptor-positive metastatic cancer.

DRUG Verzenio**GENERIC NAME** abemaciclib**DRUG INDICATION**

Verzenio is a CDK4/6 kinase inhibitor approved for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, alone or in combination with hormone therapy.

DRUG Vitrakvi**GENERIC NAME** larotrectinib**DRUG INDICATION**

Vitrakvi is a TRK inhibitor that works against cancers anywhere in the body with NTRK gene fusions.

© 2026 Smart + Strong All Rights Reserved.

http://beta.docker.cancerhealth.com/drug_charts/breast-cancer-medications-drugs